Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CALGB C80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

 


CALGB C80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer


Trial Focus

Digestive System Cancer

Objective

         This is a clinical trial of celecoxib that will be administered by mouth which is investigational and "FOLFOX"; a combination of 5-flourouracil (also called 5-FU), leucovorin and oxaliplatin that will be administered by IV and is standard of car

IRB Protocol #

10-1455

Trial Status

OPEN

Principle Investigator

STEPHEN LEONG

Sponsor

CALGB

Contact

DAVID SHENEMAN at -- or DAVID.SHENEMAN@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center University of Colorado Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 3 years.. A follow up period will consist of phone contact or clinic visit. // Eligibility criteria include but are not limited to 18 years or older with colon cancer that has spread to lymph nodes.Eligibility criteria include but are not limited to 18 years or older with colon cancer that has spread to lymph nodes.